There is now strong evidence that many of the actions of steroids in controlling reproduction are mediated by locally acting factors such as growth factors and cytokines. These have been shown to act both in an autocrine and paracrine manner to regulate preimplantation embryo development and endometrial receptivity. They also regulate trophoblast differentiation and migration which is necessary for placental development. The creation of mouse strains lacking genes for receptors or growth factors has proved important in denning which of these are essential in reproduction in this species and those that play a lesser role. Using this approach, a lack of leukaemia inhibitory factor (LIF) in the murine endometrium has been shown to result in failed implantation. Evidence from infertile women supports the notion that abnormal expression of LIF, or the related cytokine interleukin-6 (IL-6) in the endometrium may underlie some forms of human infertility. This offers the opportunity for therapeutic intervention, if levels of these cytokines can be altered in a specific and controlled way. The recently described method of delivery of genes to the uterine epithelium provides a powerful new approach by which this could be achieved. The ability to regulate the function of specific genes in the endometrium by direct gene transfer raises the prospect of novel opportunities for therapeutic intervention.
Introduction
The past 50 years has seen a revolution in the regulation of the female reproductive system with the development of steroid and now gonadotrophin therapies. These advances have led to hormonal contraception, hormone replacement therapy, ovulation induction and have facilitated the growth of assisted reproduction. In so doing they have enacted the most fundamental change in women's health which underlies the profound changes that have occurred in the biosocial status of women.
Recent developments in fertility treatments, have further diminished the consequences of severe male factor infertility. Yet despite these changes, success rates in in-vitro fertilization (IVF) remain stubbornly low, providing distress both for the individual concerned and for the economics of women's health. The weak link in this otherwise successful regulation of the female reproductive system is the endometrium. Not only is this the source of many gynaecological problems but failed implantation remains a significant cause of reproductive failure in both spontaneous and assisted menstrual cycles. Additionally there remains a need to increase the number of contraceptive options available to couples which do not act systemically because of their side-effects.
A key feature of mammalian reproduction is the interaction between hormones and local growth factors or cytokines which mediate in a paracrine or autocrine manner the signals initiated by the steroids. Understanding these relationships provides a detailed knowledge of the factors necessary for successful implantation and provides a means for therapeutic intervention.
Implantation
Implantation is a somewhat imprecise term variously described as being the time between the initiation of fertilization of the oocyte to an ill-defined time when the embryo has embedded into the endometrium and developed a placenta (Enders, 1991; Edwards, 1995) . There is remarkable variation in the cellular and molecular events of this process even between species which in other respects are considered close. Much of the understanding of implantation is based on studies in rodents which crudely share the haemochorial placentation with primates as oppossed to the epithelio-chorial placentation of ruminants (Schlafk and Enders, 1975; Enders, 1991) .
Three aspects of implantation appear essential: (i) the production of a hatched blastocyst; (ii) the development of a receptive endometrium and (iii) a dialogue between the embryo and the endometrium in order to synchronise tissue remodelling in both the embryo and the maternal environment.
Whilst many agents including steroids (Psychoyos, 1993) , adhesion molecules (Lessey et al., 1992) , serine proteases (Carmeliet et al., 1994) , matrix metalloproteinases and their inhibitors (Graham and Lala, 1991) are involved in implantation this review will concentrate on the role that secreted soluble factors, cytokines, play in the earliest stages of implantation. Finally a new means of altering gene expression in the endometrium will be described which seeks to use these soluble factors as targets for manipulating reproductive function in order to develop new therapeutic agents for fertility regulation.
Cytokines and implantation

Leukaemia inhibitory factor (LIF)
LIF is a highly glycosylated 38 kDa protein initially known for its ability to induce differentiation of Ml myeloid leukaemia cells into macrophage like-cells (Tomida et al, 1984) and to suppress embryonic stem cell differentiation (Smith et al, 1988) . It promotes haematopoietic progenitor cell survival (Fletcher et al, 1991) and also has a range of neurotrophic effects including promotion of survival for fetal sensory and motor neurons (Murphy et al., 1991; Thaler et al., 1994; Martinou et al., 1992) . Its pleiotrophic actions extend to bone metabolism, the acute phase response, myoblast proliferation and lipid metabolism, for reviews see (Hilton and Gough, 1991; Gearing, 1993) .
Mouse blastocysts express the LIF receptor components LIF-Rb and gpl30 only in the inner cell mass and express LIF in the trophectoderm (Nichols et al., 1996) . Human blastocysts also express LIF-Rb and gpl30, but do not express LIF (Sharkey et al., 1995) . In the latter case, different splice variants of gpl30 are detected following the morula to blastocyst transition, some of which are consistent with secreted truncated forms of the protein. Messenger RNA encoding LIF-Rb is only present in humans after the 8-cell stage of development (Sharkey et al., 1995) . These observations coupled with known effects of LIF on embryonic stem cells suggest that LIF might play an important role in preimplantation embryo development. Surprisingly, murine embryos deficient in LIF-Rb and gpl30 develop normally to the blastocyst stage. LIF-Rb" 7 " mice reach term though they do have abnormalities in the placenta (Ware et al, 1995) . The gpl3O" 7 " mice are more severely affected as would be expected in view of the loss of a broader range of cytokine interactions and embryos die at 12.5-18 days (Yoshida et al, 1996) . These findings suggest that in the mouse, LIF is not required for embryonic development at least up to the blastocyst stage. Nonetheless, both mouse and human embryos in vitro develop more quickly in the presence of LIF and LIF increases fetal fibronectin secretion by human 8-cell embryos, (Lavranos et al, 1995; Turpeenniemi-Hujanen et al, 1995) . LIF therefore appears to enhance embryo development, but is not essential.
In mice, LIF is up-regulated in uterine glandular epithelium on day 4, just before implantation by action of nidatory oestrogen (Bhatt et al, 1991) . Female mice lacking a functional LIF gene are unable to support implantation, although viable blastocysts are produced, which do implant upon transfer to a pseudopregnant mother (Stewart et al, 1992) . However pregnancies did occur in LIF" 7 " females when LIF was infused into the uterine lumen. Maternal expression of LIF is therefore essential for implantation in the mouse. Whilst the initial interest raised by these knockout experiments focused on the possible interactions between the maternal environment and the embryo, the results with the LIFRb" 7 " mice indicate that the effects of LIF on the endometrium are of more importance. The critical function is probably decidualization, as this does not occur in LIF" 7 " mice when oil is injected into the uterine cavity on day 5 of pseudopregnancy (Stewart, 1994) .
In humans, mRNA encoding LIF (Charnock Jones et al, 1994; Arici et al, 1995) and immunoreactivity to LIF (Charnock-Jones et al, 1994) are present in endometrium only in the luteal phase of the cycle and epithelial cells secrete more LIF than stromal cells (Chen et al, 1995; Vogiagis et al, 1996) . Two reports show that levels of LIF secretion from the endometrium in the luteal phase, may be lower in infertile women, suggesting that, as in the mouse, reduced concentrations at the time of implantation are associated with non-receptivity (Delage et al, 1995) and (Laird et al, 1997) . LIF-Rb and gp 130 mRNA is present in epithelial cells and LIF binding is confined to the luminal epithelium (Cullinan et al, 1996) . Although the mouse data indicates an important role for LIF in the endometrium, its effects on the target cells are unknown.
In the decidua, LIF appears to play an important role in controlling trophoblast invasion and placental development. Homozygous LIF-Rb"" 7 " embroyos implant, but die within 24 h of birth (Ware et al, 1995) . The placentas exhibit disrupted placental architecture, with alterations in the labyrinthine layer. All cells of the human trophoblast lineage express LIF receptor . Addition of LIF to human trophoblast cultured in vitro inhibits secretion of human chorionic gonadotrophin (HCG) and gelatinases and increases secretion of fetal fibronectin (Bischof et al, 1995; Nachtigall et al, 1996) . These changes are characteristic of cytrophoblast differentiation away from syncytiotrophoblast towards an non-invasive extravillous phenotype. LIF production by the decidua may therefore act to control trophoblast invasion during the first trimester.
Interleukin-6 (IL-6)
IL-6 shares with LIF the gp 130 signal transduction accessory signal protein in the receptor complex (Pennica et al, 1995) . In mice it is not obligatory for implantation as homozygous mice deleted for IL-6 have normal fertility (Poli et al, 1994; (Kopf et al, 1994) . However, IL-6 immunoreactivity is present in both glandular and stromal endometrium (Sharkey, 1997 ) and IL-6 synthesis is elevated at the time of implantation (Tabibzadeh and Babakania, 1995) . IL-6R is present in both the human embryo and glandular epithelium and mRNA for the receptor increases at the time of implantation (Sharkey, 1997) . In mice, IL-6 bioactivity is greatest on days 5 and 6 of pregnancy (De et al, 1993) . That aberrant expression of IL-6 may be associated with failed implantation is suggested by the finding of elevated levels in endometrium of women with an IUCD (Ammala et al, 1995) and women suffering from endometriosis and unexplained infertility (Tseng et al, 1996) . A broad range of other growth factors and cytokines have been implicated in the process of implantation. These include TNFa, CSF-1, GM-CSF-1 and IL-1 (for a reveiw see Tabibzadeh et al, 1995) .
Gene transfer
Clearly an important part of the study of implantation failure is the identification of specific cytokines which are necessary for successful implantation. This remains an academic exercise unless effective means can be identified to alter their expression. In the past the usual model would be to alter steroidal effects on endometrium in the hope that this would change cytokine levels in a desirable way. This is unlikely to be effective. An alternative approach would be to direct gene delivery to the endometrium.
The endometrium is potentially a good target because it is accessible and DNA-liposome complexes can transfer genes to ciliated secretory bronchial epithelium (Alton et al, 1993; Hyde et al, 1993) . Recently, plasmids which contain the cytomegalovirus (CMV) promoter driving either a |3-galactosidase or firefly luciferase reporter gene have been used to transfect human endometrial epithelial cells in vitro. DNA-liposome preparations were made with commercially available Lipofectamine. Human endometrial epithelial cells were transfected efficiently with ~70% of the cells staining for (3-galactosidase (CharnockJones et al, 1997) . Instillation of the DNA-liposome mixture into the uterine horn of mice on day 2 of pseudopregnancy also resulted in most cells of the endometrial epithelium being positive for (3-galactosidase. No activity was found in the ovary, spleen, liver, lung or brain of the same animals (Charnock-Jones et al, 1997) .
The high number of cells tranfected in vivo (70%) is significantly more than found in other epithelial surfaces (Grubb, 1994) . This could reflect cell specificity of the CMV promoter (Baskar et al, 1996) . The implications for women's health could be large. Whilst endometrium may be lost at menstruation, cyclical therapy to up-regulate specific gene expression is now possible. Further refinements such as cycle and tissue specific promoters could provide further fine tuning of expression. More work is needed to determine the functional efficiency of this system in both rodent and primate species before these developments can be applied to women. However, we believe these findings open a completely new approach to the investigation and potential treatment of women with reproductive failure.
Conclusions
Implantation remains the 'the last great frontier of reproductive biology'. The identification of key genes in the reproductive tract which at different stages of development control various aspects of the process is clearly an important task for the future. The ability to regulate these genes by direct gene transfer raises the prospect of exceptional opportunities for therapeutic intervention in the future.
